Aurinia Pharmaceuticals Inc (AUPH)

[puravida]

Could this be another excellent therapeutic position for voclosporin?

Everolimus is an mTOR kinase inhibitor that inhibits antigenic and interleukin (IL-2 and IL-15) stimulated activation and proliferation of T and B lymphocytes. It is indicated for prophylaxis of allograft rejection in adult liver transplant recipients in combination with reduced doses of tacrolimus and with corticosteroids.

Just read a bunch of studies that show how mTOR kinase inhibitors successfully spare or eliminate tacro/steroid dosing in transplant recipients. I wonder if Everolimus combo with low dose voclosporin without steroids would be an option for transplant recipients.

This is a link to similar application for cardiac transplants
https://pubmed.ncbi.nlm.nih.gov/25041227/